Refine
Has Fulltext
- yes (34)
Is part of the Bibliography
- yes (34)
Year of publication
- 2020 (34) (remove)
Document Type
- Journal article (22)
- Doctoral Thesis (12)
Keywords
- hypophosphatasia (4)
- bone (3)
- Bone marrow (2)
- Hip (2)
- Knieprothese (2)
- Revision (2)
- chondrocytes (2)
- mechanotransduction (2)
- myokines (2)
- osteoporosis (2)
- sarcopenia (2)
- 3D-Zellkultur (1)
- ALPL (1)
- Acetabular (1)
- Adenovirus (1)
- Anatomic reattachment (1)
- Anpassung (1)
- Arthroplasty (1)
- Aseptische Lockerung (1)
- Bauer (1)
- CCN (1)
- Cartilage (1)
- Cartilage regeneration (1)
- Case report (1)
- Chondrogenesis (1)
- Datenbank (1)
- Distal biceps tendon repair (1)
- ER signaling (1)
- Elderly patients (1)
- Endoprothetik (1)
- EnduRo (1)
- Epidemiologie (1)
- FGF23 (1)
- Fahrradergometer (1)
- Gene therapy (1)
- HPP (1)
- Hip joint (1)
- Hypertrophy (1)
- Hüfte (1)
- Hüftendoprothetik (1)
- Hüftpfanne (1)
- Hüftprothese (1)
- Joint capsule (1)
- Kapandji pinning (1)
- Kapandjidrahtosteosynthese (1)
- Klotho (1)
- Knee Endo Prostheses (1)
- Knie Endo Prothese (1)
- Kniegelenk (1)
- Kniegelenkprothese (1)
- Knievrevision (1)
- Knorpel (1)
- Kollagengel (1)
- Kranialpfanne (1)
- Ligamentum capitis femoris (1)
- Link Endo-Model (1)
- Low Dose Tranexamic acid (1)
- Lower extremity reconstruction (1)
- MLO-A5 (1)
- MLO-Y4 (1)
- MR neurography (1)
- MSCs (1)
- Mesenchymal stem cell (1)
- Mesenchymale Stammzellen (1)
- Mesenchymzelle (1)
- Mineralisation (1)
- Muskelgewebe (1)
- Muskuloskelettal (1)
- Myokine (1)
- Niedrig dosierte Tranexamsäure (1)
- Non-simultaneous bilateral distal biceps tendon rupture (1)
- Osteoarthritis (1)
- Osteogene Differenzierung (1)
- Osteozyt (1)
- Pedicled perforator flap (1)
- Press-fit (1)
- Propeller flap (1)
- Prospective Study (1)
- Prothesenlockerung (1)
- Reoperation (1)
- SOX9 (1)
- Suprascapular nerve (1)
- Suture anchor (1)
- TNAP (1)
- Tissue engineering (1)
- Total hip arthroplasty (1)
- Total knee arthroplasty (1)
- Tranexamsäure (1)
- Transgluteal approach (1)
- Transglutealer Zugang (1)
- Tumor (1)
- Vergleichsstudie (1)
- WISP-3 (1)
- Wnt/β-catenin signaling (1)
- Zugangswege (1)
- Zytokine (1)
- acetabular bone defect (1)
- aging (1)
- alkaline phosphatase (1)
- anatomic center of rotation (1)
- anterior approach (1)
- arthritis (1)
- asfotase alfa (1)
- assistive devices (1)
- asymmetric implant (1)
- bone QCT (1)
- bone fractures (1)
- bone mineral density (1)
- bone remodeling (1)
- bone tumour (1)
- calcaneus (1)
- cement (1)
- chondrogenic differentiation (1)
- clinical study (1)
- collagen gel (1)
- compression syndrome (1)
- craniosynostosis (1)
- cytokines (1)
- defects (1)
- differentiation (1)
- differentiation capacity (1)
- engineering (1)
- enzyme replacement therapy (1)
- exercise (1)
- fixation (1)
- fracture (1)
- hMSC (1)
- hMSCs (1)
- hip joint (1)
- hypovitaminosis D (1)
- implant positioning (1)
- in situ hybridization (1)
- in vitro (1)
- knee arthroplasty (1)
- knee axis (1)
- knee osteoarthritis (1)
- malignancy (1)
- mechanosensing (1)
- metabolism (1)
- mineralization (1)
- mineraliztion (1)
- model (1)
- muscle (1)
- nervous system (1)
- neuropathy (1)
- neurotransmission (1)
- nonspecific alkaline-phosphae (1)
- osteoarthritis (1)
- osteocytes (1)
- osteogenetic differentiation (1)
- osteokines adaptation (1)
- osteomalacia (1)
- osteopenia (1)
- outcome (1)
- ovariectomy (1)
- pain (1)
- patient-specific knee arthroplasty (1)
- periprosthetic infection (1)
- physical performance (1)
- promotes (1)
- proximal humerus fracture (1)
- proximale Humerusfraktur (1)
- pseudofractures (1)
- quality of life (1)
- rare bone disease (1)
- real-world evidence (1)
- reerse shoulder arthoplasty (1)
- repair (1)
- resistance exercise (1)
- revision arthroplasty (1)
- revision surgery (1)
- rickets (1)
- sanders (1)
- scaffolds (1)
- screw (1)
- shoulder arthroplasty (1)
- shoulder infection (1)
- shoulder neurolysis (1)
- spacer (1)
- stem cells (1)
- stimulation (1)
- suprascapular notch (1)
- teeth (1)
- therapy (1)
- tissue (1)
- total knee replacement (1)
- toxicity (1)
- tranexamic acid (1)
- transplantation (1)
- tumour malignancy (1)
- two stage (1)
- vertebrate (1)
- vitamin D (1)
- vitamin D deficiency (1)
- zebrafish (1)
Institute
- Lehrstuhl für Orthopädie (34) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- EU-1650-0006 (1)
Objective
As native cartilage consists of different phenotypical zones, this study aims to fabricate different types of neocartilage constructs from collagen hydrogels and human mesenchymal stromal cells (MSCs) genetically modified to express different chondrogenic factors.
Design
Human MSCs derived from bone-marrow of osteoarthritis (OA) hips were genetically modified using adenoviral vectors encoding sex-determining region Y-type high-mobility-group-box (SOX)9,transforming growth factor beta (TGFB) 1or bone morphogenetic protein (BMP) 2cDNA, placed in type I collagen hydrogels and maintained in serum-free chondrogenic media for three weeks. Control constructs contained unmodified MSCs or MSCs expressing GFP. The respective constructs were analyzed histologically, immunohistochemically, biochemically, and by qRT-PCR for chondrogenesis and hypertrophy.
Results
Chondrogenesis in MSCs was consistently and strongly induced in collagen I hydrogels by the transgenesSOX9,TGFB1andBMP2as evidenced by positive staining for proteoglycans, chondroitin-4-sulfate (CS4) and collagen (COL) type II, increased levels of glycosaminoglycan (GAG) synthesis, and expression of mRNAs associated with chondrogenesis. The control groups were entirely non-chondrogenic. The levels of hypertrophy, as judged by expression of alkaline phosphatase (ALP) and COL X on both the protein and mRNA levels revealed different stages of hypertrophy within the chondrogenic groups (BMP2>TGFB1>SOX9).
Conclusions
Different types of neocartilage with varying levels of hypertrophy could be generated from human MSCs in collagen hydrogels by transfer of genes encoding the chondrogenic factorsSOX9,TGFB1andBMP2. This technology may be harnessed for regeneration of specific zones of native cartilage upon damage.
Background
Surgical reattachment of the tendon is still the gold standard for ruptures of the distal biceps brachii tendon. Several fixation techniques have been described in the literature, with suture anchors being one of the most common fixation techniques. Currently, there is no data available on how many anchors are required for a safe and stable refixation. In this case report clinical data of a patient with non-simultaneous bilateral distal biceps tendon ruptures treated with a different number of suture anchors for each side (one vs. two) are demonstrated.
Case presentation
A 47-year-old factory worker suffered a rupture of the distal biceps tendon on both arms following two different occasions. The left side was fixed using a single suture anchor, while refixation on the right side was performed with two anchors. The patient was prospectively followed for one year. Functional outcome was assessed using the Andrews Carson Score (ACS), the Oxford Elbow Score (OES), and the Disabilities of Arm, Shoulder and Hand (DASH) Score after six, twelve, 24 and 48 weeks. Furthermore, an isokinetic strength measurement for flexion strength was performed after 24 and 48 weeks. After 48 weeks the patient presented with excellent functional outcome scores and no follow-up complications. During the follow-up period, no differences in the functional scores nor in the isokinetic flexion strength measurement could be detected. Furthermore, no radiological complications (like heterotopic ossifications) could be detected in the postoperative radiographs after one year.
Conclusions
Anatomic reattachment of the distal biceps tendon is a successful operative treatment option for distal biceps tendon ruptures. Suture anchor fixation remains one of the most common techniques, as it allows fast surgery and provides good results with respect to range of motion (ROM) and functional scoring according to the current literature. However, the number of anchors required for a stable fixation remains unclear. As indicated by our presented case, we hypothesize, that there are no significant differences between a one-point or a two-point fixation. In the presented case report, no intraindividual differences between the usage of one versus two suture anchors were evident in the short-term follow-up.
Background
Mesenchymal stem cell (MSC) based-treatments of cartilage injury are promising but impaired by high levels of hypertrophy after chondrogenic induction with several bone morphogenetic protein superfamily members (BMPs). As an alternative, this study investigates the chondrogenic induction of MSCs via adenoviral gene-delivery of the transcription factor SOX9 alone or in combination with other inducers, and comparatively explores the levels of hypertrophy and end stage differentiation in a pellet culture system in vitro.
Methods
First generation adenoviral vectors encoding SOX9, TGFB1 or IGF1 were used alone or in combination to transduce human bone marrow-derived MSCs at 5 x 10\(^2\) infectious particles/cell. Thereafter cells were placed in aggregates and maintained for three weeks in chondrogenic medium. Transgene expression was determined at the protein level (ELISA/Western blot), and aggregates were analysed histologically, immunohistochemically, biochemically and by RT-PCR for chondrogenesis and hypertrophy.
Results
SOX9 cDNA was superior to that encoding TGFB1, the typical gold standard, as an inducer of chondrogenesis in primary MSCs as evidenced by improved lacuna formation, proteoglycan and collagen type II staining, increased levels of GAG synthesis, and expression of mRNAs associated with chondrogenesis. Moreover, SOX9 modified aggregates showed a markedly lower tendency to progress towards hypertrophy, as judged by expression of the hypertrophy markers alkaline phosphatase, and collagen type X at the mRNA and protein levels.
Conclusion
Adenoviral SOX9 gene transfer induces chondrogenic differentiation of human primary MSCs in pellet culture more effectively than TGFB1 gene transfer with lower levels of chondrocyte hypertrophy after 3 weeks of in vitro culture. Such technology might enable the formation of more stable hyaline cartilage repair tissues in vivo.
Background
While multiple in vitro studies examined mesenchymal stromal cells (MSCs) derived from bone marrow or hyaline cartilage, there is little to no data about the presence of MSCs in the joint capsule or the ligamentum capitis femoris (LCF) of the hip joint. Therefore, this in vitro study examined the presence and differentiation potential of MSCs isolated from the bone marrow, arthritic hyaline cartilage, the LCF and full-thickness samples of the anterior joint capsule of the hip joint.
Methods
MSCs were isolated and multiplied in adherent monolayer cell cultures. Osteogenesis and adipogenesis were induced in monolayer cell cultures for 21 days using a differentiation medium containing specific growth factors, while chondrogenesis in the presence of TGF-ss1 was performed using pellet-culture for 27 days. Control cultures were maintained for comparison over the same duration of time. The differentiation process was analyzed using histological and immunohistochemical stainings as well as semiquantitative RT-PCR for measuring the mean expression levels of tissue-specific genes.
Results
This in vitro research showed that the isolated cells from all four donor tissues grew plastic-adherent and showed similar adipogenic and osteogenic differentiation capacity as proven by the histological detection of lipid droplets or deposits of extracellular calcium and collagen type I. After 27 days of chondrogenesis proteoglycans accumulated in the differentiated MSC-pellets from all donor tissues. Immunohistochemical staining revealed vast amounts of collagen type II in all differentiated MSC-pellets, except for those from the LCF. Interestingly, all differentiated MSCs still showed a clear increase in mean expression of adipogenic, osteogenic and chondrogenic marker genes. In addition, the examination of an exemplary selected donor sample revealed that cells from all four donor tissues were clearly positive for the surface markers CD44, CD73, CD90 and CD105 by flow cytometric analysis.
Conclusions
This study proved the presence of MSC-like cells in all four examined donor tissues of the hip joint. No significant differences were observed during osteogenic or adipogenic differentiation depending on the source of MSCs used. Further research is necessary to fully determine the tripotent differentiation potential of cells isolated from the LCF and capsule tissue of the hip joint.
The topical application of tranexamic acid (TXA) helps to prevent post-operative blood loss in total joint replacements. Despite these findings, the effects on articular and periarticular tissues remain unclear. Therefore, this in vitro study examined the effects of varying exposure times and concentrations of TXA on proliferation rates, gene expression and differentiation capacity of chondrocytes and human mesenchymal stromal cells (hMSCs), which underwent osteogenic differentiation. Chondrocytes and hMSCs were isolated and multiplied in monolayer cell cultures. Osteogenic differentiation of hMSCs was induced for 21 days using a differentiation medium containing specific growth factors. Cell proliferation was analyzed using ATP assays. Effects of TXA on cell morphology were examined via light microscopy and histological staining, while expression levels of tissue-specific genes were measured using semiquantitative RT-PCR. After treatment with 50 mg/mL of TXA, a decrease in cell proliferation rates was observed. Furthermore, treatment with concentrations of 20 mg/mL of TXA for at least 48 h led to a visible detachment of chondrocytes. TXA treatment with 50 mg/mL for at least 24 h led to a decrease in the expression of specific marker genes in chondrocytes and osteogenically differentiated hMSCs. No significant effects were observed for concentrations beyond 20 mg/mL of TXA combined with exposure times of less than 24 h. This might therefore represent a safe limit for topical application in vivo. Further research regarding in vivo conditions and effects on hMSC functionality are necessary to fully determine the effects of TXA on articular and periarticular tissues.
Background
Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by loss-of-function mutations in the ALPL gene that encodes the tissue-nonspecific alkaline phosphatase TNAP (ORPHA 436). Its clinical presentation is highly heterogeneous with a remarkably wide-ranging severity. HPP affects patients of all ages. In children HPP-related musculoskeletal symptoms may mimic rheumatologic conditions and diagnosis is often difficult and delayed. To improve the understanding of HPP in children and in order to shorten the diagnostic time span in the future we studied the natural history of the disease in our large cohort of pediatric patients. This single centre retrospective chart review included longitudinal data from 50 patients with HPP diagnosed and followed at the University Children's Hospital Wuerzburg, Germany over the last 25 years.
Results
The cohort comprises 4 (8%) perinatal, 17 (34%) infantile and 29 (58%) childhood onset HPP patients. Two patients were deceased at the time of data collection. Diagnosis was based on available characteristic clinical symptoms (in 88%), low alkaline phosphatase (AP) activity (in 96%), accumulating substrates of AP (in 58%) and X-ray findings (in 48%). Genetic analysis was performed in 48 patients (31 compound heterozygous, 15 heterozygous, 2 homozygous mutations per patient), allowing investigations on genotype-phenotype correlations. Based on anamnestic data, median age at first clinical symptoms was 3.5 months (min. 0, max. 107), while median time to diagnosis was 13 months (min. 0, max. 103). Common symptoms included: impairment of motor skills (78%), impairment of mineralization (72%), premature loss of teeth (64%), musculoskeletal pain and craniosynostosis (each 64%) and failure to thrive (62%). Up to now 20 patients started medical treatment with Asfotase alfa.
Conclusions
Reported findings support the clinical perception of HPP being a chronic multi-systemic disease with often delayed diagnosis. Our natural history information provides detailed insights into the prevalence of different symptoms, which can help to improve and shorten diagnostics and thereby lead to an optimised medical care, especially with promising therapeutic options such as enzyme-replacement-therapy with Asfotase alfa in mind.
In vorliegender Dissertation wurden die Langzeitergebnisse hinsichtlich der Lebensqualität der Patienten, die sich im Zeitraum 2002-2010 eine proximale Humerusfraktur zuzogen und mittels intramedullärer Drahtosteosynthese nach Kapandji im König Ludwig Haus in Würzburg operiert wurden, untersucht. Die Nachuntersuchung erfolgte mittels klinischer, radiologischer und sonografischer Untersuchung sowie durch Verwendung des DASH-Fragebogens, Constant Murley Score und der Visuellen Analogskala.
Eine retrospektive Studie anhand von Patientenunterlagen zum Blutverlust, Transfusionshäufigkeit und postoperativen Komplikationen bei Knie-Endo-Prothesen mit systemischer Gabe von 500 mg Tranexamsäure kurz vor Eröffnung der Blutleere! 229 Patienten in der Studiengruppe, von denen 9 eine erlaubte Wiederholungsdosis erhalten hatten, wurden verglichen mit 231 Patienten, die keine Tranexamsäure erhalten hatten. 3 Patienten der Studiengruppe gegenüber 14 Patienten der Kontrollgruppe benötigten eine Bluttransfusion. In der Studiengruppe war der niedrigste postoperative Hb bei 71,2% der Patienten 10 g/dl oder höher. In der Kontrollgruppe war es nur bei 49,4% der Patienten der Fall. Durch die Gabe von Tranexamsäure konnte der durchschnittliche, berechnete Blutverlust bei Männern von etwa 1850 ml auf 1450 ml und bei Frauen von etwa 1300 ml auf etwa 1000 ml gesenkt werden. Die Unterschiede waren signifikant! Im beobachteten Kollektiv konnte keine Steigerung der Rate an Thrombosen oder thrombembolischen Ereignissen festgestellt werden. Das Antifibrinolytikum Tranexamsäure ist in dieser niedrigen Dosierung effektiv und scheint sicher zu sein.
Hypophosphatasia (HPP) is a rare, inherited, metabolic disease caused by deficient tissue non‐specific alkaline phosphatase activity. This study aims to assess patient‐reported pain, disability and health‐related quality of life (HRQoL) in a real‐world cohort of adults with HPP who were not receiving asfotase alfa during the analysis. Adults (≥18 years old) with HPP (confirmed by ALPL gene mutation and/or low serum alkaline phosphatase activity for age/sex) were identified from the Global HPP Registry (NCT02306720). Demographics, clinical characteristics, and data on patient‐reported pain, disability, and HRQoL (assessed by Brief Pain Inventory Short Form [BPI‐SF], Health Assessment Questionnaire Disability Index [HAQ‐DI], and 36‐Item Short‐Form Health Survey version 2 [SF‐36v2], respectively) were stratified by pediatric‐ and adult‐onset HPP and summarized descriptively. Of the 304 adults included (median [min, max] age 48.6 [18.8, 79.8] years; 74% women), 45% had adult‐onset HPP and 33% had pediatric‐onset HPP (unknown age of onset, 22%). Of those with data, 38% had experienced ≥5 HPP manifestations and 62% had a history of ≥1 fracture/pseudofracture. Median (Q1, Q3) BPI‐SF scores were 3.5 (1.5, 5.3) for pain severity and 3.3 (0.9, 6.2) for pain interference. Median (Q1, Q3) disability on the HAQ‐DI was 0.3 (0.0, 0.7). Median (Q1, Q3) physical and mental component summary scores on the SF‐36v2 were 42.4 (32.7, 49.9) and 45.3 (36.3, 54.8), respectively. Greater numbers of HPP manifestations experienced/body systems affected correlated significantly with poorer scores on the BPI‐SF, HAQ‐DI, and SF‐36v2 (all p < 0.05). No significant differences between adults with pediatric‐ and adult‐onset HPP were observed for patient‐reported outcomes, except for disability and the BPI‐SF question “pain at its worst,” which were significantly higher among adults with pediatric‐ versus adult‐onset HPP (p = 0.03 and 0.04, respectively). These data from the Global HPP Registry show that adults with HPP have a substantial burden of illness that is associated with reduced patient‐reported HRQoL, regardless of age of disease onset.
Wirkung von WISP-3 auf dedifferenzierte Chondrozyten und mesenchymale Stammzellen
Degenerative Gelenkerkrankungen (Arthrosen) sind einige der häufigsten Ursachen für eine Vorstellung und Beratung in der allgemeinmedizinischen Praxis. Der Großteil der über 65-jährigen ist davon betroffen, wenn auch die Symptome in ihrer Ausprägung stark variieren können. Eine ursächliche Therapie ist bisher nicht bekannt. Es wird symptomatisch behandelt und versucht, die Symptome zu lindern und den Progress der Erkrankung zu verlangsamen. Dabei entstehen dem Gesundheitssystem durch die hohe Prävalenz nicht unerhebliche Kosten für Medikamente, Physiotherapie, Operationen und Reha-Aufenthalte.
Arthrosen beruhen auf Knorpelschädigungen, die ohne Therapie immer weiter fortschreiten können und zu Schmerzen, Bewegungseinschränkung und Verformung des Gelenks führen können. Diese Knorpelschädigungen können auf verschiedenen Ursachen beruhen wie z.B. zu hoher Belastung (bei Adipositas), Traumata oder Erkrankungen des Skelettsystems. Neue Behandlungsansätze werden mit zunehmendem Durchschnittsalter der Bevölkerung immer wichtiger werden.
Ein Ansatzpunkt ist die weitere Erforschung von Proteinen wie z.B. WISP-3, die einen positiven Effekt auf die Knorpelhomöostase bewirken. Die Bedeutung von WISP-3 fiel bei der Erforschung der Progressiven Pseudorheumatoiden Dysplasie auf, einer seltenen Gelenkerkrankung, die v.a. bei Kindern auftritt. Dabei treten auf Grund von Mutationen von WISP-3 Störungen in der Knorpelhomöostase und Gelenkarchitektur auf, die sogar eine Therapie mittels Gelenkersatz notwendig machen können.
In unseren Versuchen zeigte sich, dass WISP-3 in Verbindung mit Wachstumsfaktoren eine positive Wirkung auf das Wachstum und die Differenzierung von dedifferenzierten Chondrozyten aufweist. Somit werden neue Forschungsansätze in der Arthrosetherapie aufgezeigt. Für die weitere Forschung kann auch auf mesenchymale Stammzellen zurückgegriffen werden, die vielversprechende Aussichten besonders im Tissue Engineering bieten.
Für die gesamte CCN-Familie ergeben sich noch weitere vielfältige Forschungsmöglichkeiten, wie z.B. in der Therapie von Mamma-, Gebärmutter- oder Nierenzellkarzinomen.